These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 9780183

  • 1. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.
    Yamamoto M, Briles DE, Yamamoto S, Ohmura M, Kiyono H, McGhee JR.
    J Immunol; 1998 Oct 15; 161(8):4115-21. PubMed ID: 9780183
    [Abstract] [Full Text] [Related]

  • 2. Protective immunity to Streptococcus mutans induced by nasal vaccination with surface protein antigen and mutant cholera toxin adjuvant.
    Saito M, Otake S, Ohmura M, Hirasawa M, Takada K, Mega J, Takahashi I, Kiyono H, McGhee JR, Takeda Y, Yamamoto M.
    J Infect Dis; 2001 Mar 01; 183(5):823-6. PubMed ID: 11181162
    [Abstract] [Full Text] [Related]

  • 3. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH.
    Vaccine; 2011 Aug 05; 29(34):5731-9. PubMed ID: 21696869
    [Abstract] [Full Text] [Related]

  • 4. A combination of Flt3 ligand cDNA and CpG oligodeoxynucleotide as nasal adjuvant elicits protective secretory-IgA immunity to Streptococcus pneumoniae in aged mice.
    Fukuyama Y, King JD, Kataoka K, Kobayashi R, Gilbert RS, Hollingshead SK, Briles DE, Fujihashi K.
    J Immunol; 2011 Feb 15; 186(4):2454-61. PubMed ID: 21242514
    [Abstract] [Full Text] [Related]

  • 5. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.
    Yamamoto M, McDaniel LS, Kawabata K, Briles DE, Jackson RJ, McGhee JR, Kiyono H.
    Infect Immun; 1997 Feb 15; 65(2):640-4. PubMed ID: 9009325
    [Abstract] [Full Text] [Related]

  • 6. Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae.
    Fukuyama Y, King JD, Kataoka K, Kobayashi R, Gilbert RS, Oishi K, Hollingshead SK, Briles DE, Fujihashi K.
    J Immunol; 2010 Aug 01; 185(3):1755-62. PubMed ID: 20585031
    [Abstract] [Full Text] [Related]

  • 7. Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in mice.
    Ezoe H, Akeda Y, Piao Z, Aoshi T, Koyama S, Tanimoto T, Ishii KJ, Oishi K.
    Vaccine; 2011 Feb 17; 29(9):1754-61. PubMed ID: 21219977
    [Abstract] [Full Text] [Related]

  • 8. Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice.
    Oma K, Zhao J, Ezoe H, Akeda Y, Koyama S, Ishii KJ, Kataoka K, Oishi K.
    Vaccine; 2009 May 21; 27(24):3181-8. PubMed ID: 19446189
    [Abstract] [Full Text] [Related]

  • 9. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4.
    Marinaro M, Staats HF, Hiroi T, Jackson RJ, Coste M, Boyaka PN, Okahashi N, Yamamoto M, Kiyono H, Bluethmann H, Fujihashi K, McGhee JR.
    J Immunol; 1995 Nov 15; 155(10):4621-9. PubMed ID: 7594461
    [Abstract] [Full Text] [Related]

  • 10. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues.
    Imaoka K, Miller CJ, Kubota M, McChesney MB, Lohman B, Yamamoto M, Fujihashi K, Someya K, Honda M, McGhee JR, Kiyono H.
    J Immunol; 1998 Dec 01; 161(11):5952-8. PubMed ID: 9834076
    [Abstract] [Full Text] [Related]

  • 11. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice.
    Nyström-Asklin J, Adamsson J, Harandi AM.
    Scand J Immunol; 2008 May 01; 67(5):431-40. PubMed ID: 18298617
    [Abstract] [Full Text] [Related]

  • 12. IL-12 is an effective adjuvant for induction of mucosal immunity.
    Boyaka PN, Marinaro M, Jackson RJ, Menon S, Kiyono H, Jirillo E, McGhee JR.
    J Immunol; 1999 Jan 01; 162(1):122-8. PubMed ID: 9886377
    [Abstract] [Full Text] [Related]

  • 13. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice.
    Strindelius L, Filler M, Sjöholm I.
    Vaccine; 2004 Sep 09; 22(27-28):3797-808. PubMed ID: 15315861
    [Abstract] [Full Text] [Related]

  • 14. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin.
    Marinaro M, Boyaka PN, Jackson RJ, Finkelman FD, Kiyono H, Jirillo E, McGhee JR.
    J Immunol; 1999 Jan 01; 162(1):114-21. PubMed ID: 9886376
    [Abstract] [Full Text] [Related]

  • 15. Oral immunization with simian immunodeficiency virus p55gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates.
    Kubota M, Miller CJ, Imaoka K, Kawabata S, Fujihashi K, McGhee JR, Kiyono H.
    J Immunol; 1997 Jun 01; 158(11):5321-9. PubMed ID: 9164952
    [Abstract] [Full Text] [Related]

  • 16. Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin.
    Ohmura M, Yamamoto M, Kiyono H, Fujihashi K, Takeda Y, McGhee JR.
    Vaccine; 2001 Dec 12; 20(5-6):756-62. PubMed ID: 11738739
    [Abstract] [Full Text] [Related]

  • 17. Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity.
    Ohmura-Hoshino M, Yamamoto M, Yuki Y, Takeda Y, Kiyono H.
    Vaccine; 2004 Sep 09; 22(27-28):3751-61. PubMed ID: 15315856
    [Abstract] [Full Text] [Related]

  • 18. Mucosal immunization with polyamine transport protein D (PotD) protects mice against nasopharyngeal colonization with Streptococcus pneumoniae.
    Shah P, Briles DE, King J, Hale Y, Swiatlo E.
    Exp Biol Med (Maywood); 2009 Apr 09; 234(4):403-9. PubMed ID: 19176871
    [Abstract] [Full Text] [Related]

  • 19. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.
    Briles DE, Hollingshead SK, King J, Swift A, Braun PA, Park MK, Ferguson LM, Nahm MH, Nabors GS.
    J Infect Dis; 2000 Dec 09; 182(6):1694-701. PubMed ID: 11069242
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.